ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, asciminib, with its novel mechanism specifically targeting the ABL myristoyl pocket, is safe, well tolerated, and provides durable longer-term responses, including DMR in heavily pretreated patients with CML-CP without T315I.